Sponsor

Hutchison Medipharma Limited

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Hutchison Medipharma Limited appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

13 shown
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerNCT05509699 · lead sponsor · 2022-09-27
COMPLETED
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationNCT05015608 · lead sponsor · 2021-11-22
COMPLETED
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsNCT04923945 · lead sponsor · 2021-08-19
COMPLETED
Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLCNCT03684967 · lead sponsor · 2018-05-08
WITHDRAWN
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersNCT03251378 · lead sponsor · 2017-12-11
COMPLETED
A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerNCT02897479 · lead sponsor · 2016-12-01
UNKNOWN
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerNCT02976116 · lead sponsor · 2016-12-01
COMPLETED
A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerNCT02691299 · lead sponsor · 2015-12-09
COMPLETED
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCNCT02374645 · lead sponsor · 2015-04-01
COMPLETED
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerNCT02590965 · lead sponsor · 2014-05-29
COMPLETED
A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523NCT02105129 · lead sponsor · 2014-05-01
COMPLETED
Safety and Efficacy of Genolimzumab (GB226) in Combination With FruquintinibNCT03976856 · collaborator · 2019-07-23
UNKNOWN
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibNCT03778229 · collaborator · 2019-01-09
ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Hutchison Medipharma Limited as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
fruquintinib5
placebo4
gefitinib2
osimertinib1
fruquintinib RxCUI 2670179 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 5 trials placebo RxCUI 8375 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials gefitinib RxCUI 328134 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials osimertinib RxCUI 1721560 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor11
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.